opinion: stiff price controls will hurt access to ground-breaking drugs
the federal patented medicines price review board thinks companies would be happy to sell canada their new drugs for much less than they get in many other 36 oecd countries. it doesn’t look like they’re right.
patients reveal thoughts on high-cost drug strategy
patients and their families said they want more transparency about how drug pricing for rare diseases works.